Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV
infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day.
All patients will be required to have at least one high-risk criteria.